Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results